Sanofi already controls both the incumbent Pompe molecule and the KFSH&RC home-infusion relationship a new ERT entrant must replicate from scratch.

Alglucosidase alfa (Lumizyme/Myozyme) is SFDA-registered and NPHC-covered as the entrenched GCC standard of care, with Sanofi running an established home-infusion pilot at KFSH&RC since 2022-2024 covering roughly 30 patients in Riyadh. Avalglucosidase alfa (Nexviazyme), Sanofi's own next-generation ERT, has a pending or recent SFDA registration with NPHC switch criteria still forming, meaning Sanofi is managing its own internal cannibalisation, and any external new entrant faces a company that already controls both the incumbent molecule and the infrastructure relationship.

GCC late-onset Pompe prevalence is consanguinity-elevated at an estimated 1 in 25,000-35,000, versus a global 1 in 57,000, yielding 400-600 total GCC patients, of whom 200-300 are on ERT. The most actionable segment is narrower: 40-60 patients with declining lung function despite alglucosidase, already on home non-invasive ventilation, representing inadequate responders. Reaching them requires clearing the NPHC step-edit, 12 months of documented alglucosidase failure, or an ADA-positive pathway that can waive the wait if a high-titre antibody response is confirmed via KFSH&RC's assay. Adult diagnosis itself is delayed 8-12 years in GCC, longer than the US's 7-10, due to lower enzyme-testing awareness.

The step-edit and Sanofi's infrastructure gate entry here, not the molecule itself.

Five questions this report answers:

Q1 - What must a new ERT prove to clear the NPHC step-edit against Sanofi's entrenched position?

Q2 - How large is the ADA-positive inadequate-responder and undiagnosed adult population, and how is it found?

Q3 - What NPHC and home-infusion groundwork needs to start before launch?

Q4 - What determines whether a pre-launch late-onset Pompe disease ERT succeeds commercially in the GCC?

Q5 - What deliverables and sourcing standard back every AXLRx GCC Pompe assessment?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#PompeDisease #GCC #SFDA #RareDisease #LaunchReadiness #Neuromuscular

Live report page:  https://axlrx.ai/pompe-disease/gcc/launch-readiness/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-     hello@axlrx.ai

Web-     https://axlrx.ai/